<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02359149</url>
  </required_header>
  <id_info>
    <org_study_id>2014/1719</org_study_id>
    <nct_id>NCT02359149</nct_id>
  </id_info>
  <brief_title>Intravitreal Injections by Nurses and Physicians Compared</brief_title>
  <official_title>Intravitreal Injections by Nurses or Physicians: a Randomized Controlled Trial Comparing Efficacy, Patient Satisfaction and Health Economy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-VEGF agents are given for a variety of previously untreatable eye diseases. The last
      years indications for their use and consequently the number of patients needing treatment,
      have been increasing. Most patients require multiple injections. This has resulted in many
      eye departments administering thousands of injections per year, also at St Olavs University
      Hospital Trondheim. To cope with this increase in workload, it would be helpful if injections
      would be given not only by the physicians but also by the nurses. This study's objective is
      to compare efficiency, patient satisfaction and cost per patient of injections given by
      nurses and physicians.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">March 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in visual acuity</measure>
    <time_frame>1 year</time_frame>
    <description>Mean change in visual acuity from baseline to 12 months, tested on ETDRS letter chart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of ocular adverse events</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>12 months</time_frame>
    <description>questionnaire after the first treatment will be compared with questionnaire after 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">328</enrollment>
  <condition>Eye Diseases</condition>
  <arm_group>
    <arm_group_label>nurse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravitreal injections with anti-VEGF agents given by a nurse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>physician</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravitreal injections with anti-VEGF agents given by a physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intravitreal injections given by a nurse</intervention_name>
    <arm_group_label>nurse</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intravitreal injections given by a physician</intervention_name>
    <arm_group_label>physician</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravitreal injections</intervention_name>
    <arm_group_label>nurse</arm_group_label>
    <arm_group_label>physician</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-VEGF agents</intervention_name>
    <arm_group_label>nurse</arm_group_label>
    <arm_group_label>physician</arm_group_label>
    <other_name>anti vasculer endothelial growth factor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  referred to the eye clinic for treatment of age related macular degeneration, diabetes
             retinopathy or retinal vein occlusion with anti-vascular endothelium growth factor

          -  Ability to provide written informed consent

          -  ability to comply with study assessments for the full duration of the study

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marit Fagerli, md</last_name>
    <role>Study Director</role>
    <affiliation>St Olavs University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Olavs Hospital, Department of Ophthalmology</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Austeng D, Morken TS, Bolme S, Follestad T, Halsteinli V. Nurse-administered intravitreal injections of anti-VEGF: study protocol for noninferiority randomized controlled trial of safety, cost and patient satisfaction. BMC Ophthalmol. 2016 Oct 1;16(1):169.</citation>
    <PMID>27716253</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2015</study_first_submitted>
  <study_first_submitted_qc>February 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2015</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intravitreal injections</keyword>
  <keyword>Nurses</keyword>
  <keyword>Physicians</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

